Earnings call Nektar Therapeutics progresses with key clinical studies
| RYCFX Fund | USD 53.95 0.65 1.22% |
Slightly above 51% of Biotechnology Fund's investors are presently thinking to get in. The analysis of overall sentiment of trading Biotechnology Fund Class mutual fund suggests that some investors are interested at this time. Biotechnology Fund's investing sentiment can be driven by a variety of factors including economic data, Biotechnology Fund's earnings reports, geopolitical events, and overall market trends.
BIOTECHNOLOGY |
Earnings call Nektar Therapeutics progresses with key clinical studies
Read at investing.com
 |
Biotechnology Fund Fundamental Analysis
We analyze Biotechnology Fund's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Fund using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Fund based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Three Year Return
Three Year Return Comparative Analysis
Biotechnology Fund is currently under evaluation in three year return among similar funds. Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
Biotechnology Fund Class Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biotechnology Fund mutual fund to make a market-neutral strategy. Peer analysis of Biotechnology Fund could also be used in its relative valuation, which is a method of valuing Biotechnology Fund by comparing valuation metrics with similar companies.
Peers
Biotechnology Fund Related Equities
| SHISX | Blackrock Health | 0.50 | ||||
| SHSKX | Blackrock Health | 0.49 | ||||
| ITRAX | Vy(r) T | 0.04 | ||||
| ERSMX | Eaton Vance | 0.33 |
Other Information on Investing in BIOTECHNOLOGY Mutual Fund
Biotechnology Fund financial ratios help investors to determine whether BIOTECHNOLOGY Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIOTECHNOLOGY with respect to the benefits of owning Biotechnology Fund security.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |